On April 15, 2026 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported that it will present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held from April 17–22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation will include details around the IND-enabling activities for the company’s potent STING Agonist, IMGS-203, for the treatment of GBM. This therapy is designed for intratumoral delivery, enabling localized immune activation with minimal systemic exposure. In orthotopic GBM models, IMGS-203 demonstrated robust anti-tumor activity and significant survival benefit. The data support a clear translational path, with pharmacologic activity confirmed across multiple species and pilot toxicology studies informing dose and delivery parameters for the GLP toxicology study and eventual clinical trial.

"IMGS-203 combines potent STING activation with a localized delivery approach designed to overcome the immunosuppressive tumor microenvironment in GBM," said Dr. Federica Pericle, Chief Scientific Officer of ImmunoGenesis. "These data support the advancement of IMGS-203 toward clinical development."

IMGS-203 Presentation Details:
GBM is a lethal malignancy with a highly immunosuppressive tumor microenvironment (TME) enriched in myeloid-derived suppressor cells, tumor-associated macrophages, and tumor-associated neutrophils. IMGS-203 is a potent STING agonist developed for intratumoral (IT) delivery, a route of administration (ROA) particularly suited for GBM, a tumor that rarely metastasizes and is readily accessible for local delivery during standard procedures such as biopsy. In vitro assays and preclinical murine studies, including a humanized model with epigenetically silenced STING, demonstrated the antitumor efficacy, specificity, and mechanism of action of IMGS-203. These studies also provided pharmacokinetic data and supported its translational potential for local delivery.

Title:

IND-enabling development of a novel STING agonist, IMGS-203, for the treatment of glioblastoma

Abstract Number:

4300

Date and Time:

Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PT

Session:

Immunomodulatory Agents

Location:

Poster Section 8, Poster Board Number 4

For more information and to view the Company’s abstract, visit the AACR (Free AACR Whitepaper) Annual Meeting website.

(Press release, ImmunoGenesis, APR 15, 2026, View Source [SID1234664409])

On April 15, 2026 Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim’s DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab’s DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently need more effective treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The strategy to engage the immune system with a specific T‑cell engager and deliver a potent cytotoxic payload with a DLL3‑targeting ADC, aligns with our immuno‑oncology strategy and our drive to advance smart combinations for hard‑to‑treat cancers," said Itziar Canamasas, Ph.D., Global Head of Oncology at Boehringer Ingelheim. "It’s another step in our mission to expand effective options for people with DLL3‑expressing cancers."

"Zoci has shown encouraging activity and good tolerability in SCLC," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "We have rapidly advanced zoci into pivotal stage and are pursuing opportunities to explore multiple combination approaches in SCLC and other NECs. This collaboration with Boehringer Ingelheim offers a compelling DLL3‑targeting strategy with the potential to benefit patients who urgently need better treatments."

Obrixtamig is Boehringer Ingelheim’s investigational bispecific DLL3/CD3 T‑cell engager, designed to direct the body’s own immune cells to attack DLL3‑expressing cancer cells, a hallmark of SCLC and certain NECs. In the global Phase I first‑line ES‑SCLC study DAREON‑8, in combination with chemotherapy and atezolizumab, obrixtamig showed encouraging signs of early clinical efficacy and a manageable safety profile1. Obrixtamig is being evaluated across multiple global studies and is advancing into a global Phase III trial (DAREON‑Lung‑1, NCT07472517). The molecule has received FDA Fast Track Designation and Orphan Drug Designation from both the FDA and the European Commission for neuroendocrine carcinomas.

Zocilurtatug pelitecan is Zai Lab’s DLL3targeting ADC engineered to deliver a potent cytotoxic payload to DLL3positive tumor cells in ES-SCLC. Updated global Phase I results in previously treated ES-SCLC show strong and durable responses, including in patients with brain metastases, along with a favorable safety profile. On this basis, the program has advanced into a global Phase III registrational study. In addition to SCLC, zoci is being evaluated in NECs. Zoci has received FDA Orphan Drug Designation and FDA Fast Track Designation for the treatment of SCLC.

Under the terms of the agreement, Zai Lab will supply its DLL3‑targeting ADC for the study, while Boehringer Ingelheim will sponsor and oversee day‑to‑day clinical operations. Each company retains the rights to its respective assets.

(Press release, Boehringer Ingelheim, APR 15, 2026, View Source [SID1234664425])

On April 15, 2026 OncoHost, a technology company transforming precision oncology through proteomics-based biomarker development, reported its acceptance to present a scientific poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "Proteomic aging biomarkers predict survival in immunotherapy-treated tumors," explores the application of plasma proteomics to quantify biological aging and its clinical implications across multiple cancer types. By leveraging organismal and organ-specific proteomic aging models, the study evaluates how aging-related biological processes correlate with tumor characteristics, patient characteristics, and treatment outcomes.

"This research expands our understanding of how systemic and organ-specific aging processes influence cancer biology and response to immunotherapy," said Michal Harel, Ph.D., VP Translational Medicine at OncoHost and lead author of the study. "By capturing both systemic biological aging and organ-specific aging across multiple tissues, we are uncovering clinically relevant signals that go beyond traditional biomarkers and may help refine patient stratification."

The study analyzed deep plasma proteomic profiles from patients with metastatic solid tumors, including NSCLC, SCLC, renal cell carcinoma (RCC), and melanoma, alongside healthy controls. Results demonstrated that cancer patients exhibit significantly elevated biological age compared to healthy individuals, with lung age gap highest in NSCLC and SCLC, and kidney age gap most significant in RCC. In addition, organ-specific aging patterns were associated with relevant comorbidities, reinforcing the systemic nature of cancer-related aging.

Furthermore, the findings highlight the prognostic value of immune-specific aging for benefit from immunotherapy. Among patients treated with immune checkpoint inhibitors, those with a high immune age gap had significantly shorter overall survival compared to those with a low immune age gap (median OS: 16.4 vs. 31.8 months; HR=0.67, p<0.0001 The effect varied by indication, with the strongest signal observed in melanoma (HR = 0.27, p = 0.0007) and no effect in SCLC (HR = 0.87, p = 0.65), potentially reflecting differences in tumor immunogenicity.

"Being selected to present at AACR (Free AACR Whitepaper) highlights the power of moving beyond tumor-centric thinking," said Ofer Sharon, MD, CEO of OncoHost. "By quantifying biological aging across the body, and specifically the immune system, we are uncovering a new layer of insight into cancer progression and treatment response – one that has the potential to transform how we guide immunotherapy, ultimately enabling more informed treatment decisions and improved patient outcomes."

Poster Presentation Details
Title: Proteomic aging biomarkers predict survival in immunotherapy-treated tumors
Session Title: Biomarkers Predictive of Therapeutic Benefit 3
Poster Board #: 22
Presenters: Michal Harel, PhD, VP Translational Medicine, OncoHost & Adam Dicker, MD, PhD, Chief Medical Officer, OncoHost
Date & Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM PDT

The abstract is available on the AACR (Free AACR Whitepaper) website here.

(Press release, OncoHost, APR 15, 2026, View Source [SID1234664410])

On April 15, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Building on our longstanding scientific leadership and recent clinical progress, Tango has a unique opportunity with vopimetostat to bring a potentially paradigm-shifting treatment to patients with pancreatic and other cancers," said Malte Peters, MD, President and Chief Executive Officer. "In order to support our goal and drive Tango’s next phase of growth, we have strengthened our development, corporate strategy and finance leadership to accelerate and support our efforts in late-stage development and potential commercialization. I extend my gratitude to our prior Chief Financial Officer, Daniella Beckman, for her many contributions to Tango since its inception, including taking the Company public and leading multiple capital raises. We wish her well in future endeavors. We look forward to presenting key clinical data this year, including initial data from our combination trial with Revolution Medicines, Inc.’s RAS(ON) inhibitors."

Matthew Gall has been appointed Chief Financial Officer effective April 15, succeeding Daniella Beckman. Mr. Gall is a seasoned biotechnology executive with extensive finance, corporate development, strategic transaction and capital raising experience. Previously, he was Chief Financial Officer at Kalaris Therapeutics and iTeos Therapeutics, and held finance, business development and corporate strategy roles at Sarepta Therapeutics, Celgene Corporation and Gilead Sciences.

Yen-Ching Chua has been appointed Chief Development Operations Officer effective June 1, overseeing clinical operations including data management, as well as quality, clinical compliance and clinical sourcing. She brings deep global experience, having previously led clinical and development operations across complex global portfolios at Novocure, Debiopharm International, MorphoSys and Novartis.

In addition, Janice Kapty, PhD has been appointed SVP, Corporate Strategy and Project Leadership, effective April 15. In this role, she will be responsible for portfolio strategy, oversee the project management organization, and ensure strong project leadership for vopimetostat and portfolio therapies, including TNG456. Previously, Dr. Kapty led drug development teams at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene Corporation.

(Press release, Tango Therapeutics, APR 15, 2026, View Source [SID1234664426])

On April 15, 2026 Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, reported a $28 million investment from its parent company, HLB Innovation (KOSDAQ: 024850). The investment comes ahead of a significant clinical milestone: the first-ever presentation of KIR-CAR clinical data, which will be featured in the Late-Breaking Clinical Trials plenary session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, CA, on April 20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funding will support ongoing Phase 1 clinical trials of Verismo’s two KIR-CAR programs currently in the clinic: SynKIR-110 in patients with advanced mesothelin-expressing solid tumors (STAR-101, NCT05568680) and SynKIR-310 in patients with relapsed/refractory B cell non-Hodgkin lymphomas (CELESTIAL-301, NCT06544265).

Selection for an AACR (Free AACR Whitepaper) Late-Breaking Clinical Trials plenary session is among the most prestigious distinctions in oncology research. The upcoming STAR-101 presentation marks Verismo’s first-ever presentation of clinical data on a KIR-CAR candidate.

"This investment from HLB Innovation comes at a pivotal moment for Verismo and for the KIR-CAR platform," said Bryan Kim, CEO and Co-Founder of Verismo Therapeutics. "This funding ensures we have the resources to fully capitalize on that momentum — advancing our solid tumor and blood cancer programs toward the data readouts that will define the potential for multi-chain KIR-CAR cell therapy to provide durable results over current single-chain CAR Ts."

The following data readouts will be presented at the upcoming AACR (Free AACR Whitepaper) 2026, reflecting the breadth of Verismo’s novel KIR-CAR platform:

Late-Breaking Clinical Trials Plenary Session — April 20, 2026: Initial results of a first-in-human dose-escalation study of KIR-CAR in patients with advanced mesothelin-expressing solid tumors
Poster Presentation — April 21, 2026: Novel SynKIR-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B cell non-Hodgkin lymphoma xenograft mice and shows early clinical signal
Late-Breaking Poster Presentation — April 20, 2026: Natural killer cell-based signaling in EGFR-targeted KIR-CAR T overcomes CD3-based CAR T functional deficits to eliminate resistant glioblastomas in vivo

(Press release, Verismo Therapeutics, APR 15, 2026, View Source [SID1234664411])